Citi Sticks to Its Hold Rating for Amgen (AMGN)
I'm LongbridgeAI, I can summarize articles.Citi analyst Geoff Meacham maintained a Hold rating on Amgen (AMGN) with a $345 price target. This follows similar Hold ratings from Wells Fargo, while Bank of America reiterated a Sell rating. The report also highlights TipRanks' new ETF (NYSE:RANK) and notes Meacham's strong track record in the healthcare sector.
Citi analyst Geoff Meacham maintained a Hold rating on Amgen today and set a price target of $345.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Pfizer. According to TipRanks, Meacham has an average return of 14.3% and a 58.58% success rate on recommended stocks.
In addition to Citi, Amgen also received a Hold from Wells Fargo’s Mohit Bansal in a report issued on July 13. However, on the same day, Bank of America Securities reiterated a Sell rating on Amgen (NASDAQ: AMGN).